Corcept Therapeutics (NASDAQ:CORT) Raised to "Peer Perform" at Wolfe Research

Key Points

• FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel for platinum‑resistant ovarian cancer sparked a ~19.7% rally and prompted analyst re‑ratings (Wolfe upgraded to "peer perform", Truist to "strong‑buy"), while consensus remains a Moderate Buy with a $76 price target.
• Corcept's most recent quarter missed estimates—EPS $0.20 vs. $0.33 expected and revenue $202.1M vs. $254.9M—though revenue was up 11.1% year‑over‑year.
• Insider activity is mixed: a director bought 100,000 shares (~$3.31M) in mid‑March but other insiders have sold recently, and multiple law firms have filed securities‑class‑action alerts that pose a potential legal overhang.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) was upgraded by analysts at Wolfe Research from an "underperform" rating to a "peer perform" rating in a research report issued on Thursday.

A number of other research analysts also recently issued reports on the company. Zacks Research downgraded Corcept Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, January 13th. Weiss Ratings reiterated a "hold (c)" rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. HC Wainwright dropped their price target on shares of Corcept Therapeutics from $67.00 to $60.00 and set a "buy" rating on the stock in a research report on Wednesday. Truist Financial upgraded shares of Corcept Therapeutics to a "strong-buy" rating in a research report on Wednesday. Finally, UBS Group initiated coverage on shares of Corcept Therapeutics in a research note on Tuesday, December 16th. They set a "neutral" rating and a $95.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $76.00.

Corcept Therapeutics Stock Up 19.7%

NASDAQ:CORT opened at $40.47 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.92 and a quick ratio of 2.85. The company's fifty day moving average price is $37.41 and its 200-day moving average price is $61.15. Corcept Therapeutics has a 1-year low of $28.66 and a 1-year high of $117.33. The firm has a market capitalization of $4.30 billion, a P/E ratio of 49.35 and a beta of 0.29.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.13). Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The business had revenue of $202.13 million for the quarter, compared to analyst estimates of $254.94 million. During the same quarter in the prior year, the firm earned $0.26 earnings per share. The company's revenue for the quarter was up 11.1% on a year-over-year basis. As a group, equities research analysts anticipate that Corcept Therapeutics will post 1.36 EPS for the current year.

Insiders Place Their Bets

In other Corcept Therapeutics news, insider William Guyer sold 20,000 shares of the company's stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $40.87, for a total transaction of $817,400.00. Following the completion of the transaction, the insider directly owned 1,235 shares in the company, valued at approximately $50,474.45. This represents a 94.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director G Leonard Baker, Jr. acquired 100,000 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was purchased at an average price of $33.14 per share, for a total transaction of $3,314,000.00. Following the completion of the acquisition, the director owned 1,146,631 shares in the company, valued at $37,999,351.34. The trade was a 9.55% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have sold 60,000 shares of company stock valued at $2,241,035 over the last 90 days. 20.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Abacus FCF Advisors LLC acquired a new stake in shares of Corcept Therapeutics in the 3rd quarter worth $3,238,000. JPMorgan Chase & Co. increased its position in Corcept Therapeutics by 223.4% during the third quarter. JPMorgan Chase & Co. now owns 849,864 shares of the biotechnology company's stock worth $70,632,000 after purchasing an additional 587,053 shares during the last quarter. Pacer Advisors Inc. boosted its holdings in Corcept Therapeutics by 6,796.7% in the 3rd quarter. Pacer Advisors Inc. now owns 390,559 shares of the biotechnology company's stock valued at $32,459,000 after purchasing an additional 384,896 shares during the last quarter. Brown Capital Management LLC purchased a new stake in shares of Corcept Therapeutics in the 3rd quarter valued at approximately $19,950,000. Finally, Cerity Partners LLC increased its holdings in shares of Corcept Therapeutics by 21.4% during the 2nd quarter. Cerity Partners LLC now owns 746,593 shares of the biotechnology company's stock worth $54,800,000 after buying an additional 131,799 shares during the last quarter. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: FDA approval of Lifyorli plus nab‑paclitaxel for platinum‑resistant ovarian cancer — major commercial catalyst (approval completed ahead of schedule; trial showed survival benefit). BusinessWire: FDA Approval
• Positive Sentiment: Analyst support and upgrades — Truist moved to “strong‑buy” and H.C. Wainwright reiterated buy with a $60 target, supporting demand as investors re‑price upside now that FDA risk is resolved for this indication. Coverage (TickerReport/Zacks)
• Positive Sentiment: Insider director purchase in mid‑March (100,000 shares) cited by market commentators as a confidence signal and likely amplified bullish positioning ahead of the approval. QuiverQuant: Insider Buy
• Neutral Sentiment: Trading halt (LULD pause) and very large intraday swings — market‑structure volatility response to the approval and heavy volume; expect continued short‑term price volatility. Reuters: Market Reaction
• Neutral Sentiment: Short-interest entries in some feeds appear inconsistent/erroneous (reported zeros); do not rely on those figures until clearing updates are posted.
• Negative Sentiment: Multiple law firms have filed or issued alerts about securities‑class‑action suits alleging disclosure issues tied to prior regulatory and patent matters — these proceedings (and the April 21 lead‑plaintiff deadline) are a material legal overhang that could pressure stock or divert cash/management attention. GlobeNewswire: Hagens Berman Alert
• Negative Sentiment: Recent insider selling: William Guyer sold ~11,767 shares on March 20 (~$423.7k), reducing his stake substantially — may be perceived negatively despite offsetting director buy. InsiderTrades: William Guyer Sale

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.